Healthcare / BiotechnologyTokyo
$411.00
-12.00 (-2.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-105.3M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
13.3x
↓EV/EBITDA
N/A
•ROE
-32.9%
↓Gross Margin
72.5%
↑Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
0.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.54B · net income $-448.9M · FCF $-105.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.54B | $1.54B | $1.72B | $2.12B | $1.32B |
| Net Income | $-448.9M | $-448.9M | $26.4M | $493.3M | $-388.0M |
| EBITDA | $-399.4M | $-399.4M | $87.9M | $537.4M | $-305.8M |
| EPS | -110.99 | -110.99 | 6.98 | 97.29 | -117.50 |
| Gross Margin | 72.5% | 72.5% | 69.7% | 73.3% | 54.9% |
| Operating Margin | -9.2% | -9.2% | 0.6% | 23.9% | -12.7% |
| Net Margin | -29.1% | -29.1% | 1.5% | 23.2% | -29.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.40 | 0.75 | 1.25 |
| Current Ratio | 4.41 | 4.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-105.3M | $-105.3M | $-118.1M | $265.1M | $9.6M |
| Returns | |||||
| ROE | -32.9% | -32.9% | 1.5% | 32.6% | -46.8% |
| Valuation | |||||
| P/E | 13.35 | 13.35 | 69.48 | 5.88 | — |
| EV/EBITDA | — | — | 13.34 | 2.82 | — |
| P/B | 1.22 | 1.22 | 1.02 | 1.28 | 2.19 |
| Growth & Yield | |||||
| Revenue Growth | -10.1% | -10.1% | -19.2% | 60.3% | — |
| EPS Growth | -1690.1% | -1690.1% | -92.8% | 182.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.0%
Start / end P/E
n/dx → n/dx
EPS bridge
6.98 → -110.99
Residual
+9.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.